This analysis examines the historical and forecast performance for Merck & Co. in the ethical pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information.
Scope
Highlights of this title
Key reasons to purchase this title
- Benchmark Merck & Co.s performance against key rivals in the ethical pharmaceutical sector
- Assess the sales growth potential of the key first-in-class drug launches Januvia and Gardasil
- Analyze Merck & Co.s continued recovery from the 2004 withdrawal of Vioxx and 2006 loss of Zocor US patent protection
